BioGPS
  • Home
  • Help
  • Plugins
  • Datasets
  • Sign Up
  • Login
Examples: Gene Symbol(s), Gene Ontology, Splicing plugins, Melanoma datasets
advanced
Home › Dataset Library › Pneumonia infection, lung and liver inflammation

Dataset: Pneumonia infection, lung and liver inflammation

Vaccination reduces morbidity and mortality from pneumonia but its effect on the tissue-level response to infection is still poorly...

Registered by ArrayExpress Uploader
View Dataset

Vaccination reduces morbidity and mortality from pneumonia but its effect on the tissue-level response to infection is still poorly understood. We evaluated pneumonia disease progression, acute phase response and lung gene expression profiles in mice inoculated intranasally with virulent gram-positive Streptococcus pneumoniae serotype (ST) 3, with and without prior immunization with pneumococcal polysaccharide ST 3 (PPS3), or co-immunization with PPS3 and with a low dose of lipopolysaccharide (LPS). Pneumonia severity was assessed in the acute phase, 5, 12, 24 and 48 h post-inoculation (p.i.) and the resolution phase of 7 days p.i. Primary PPS3 specific antibody production was upregulated and IgM binding to pneumococci increased in PPS3-immunized mice. Immunizations with PPS3 or PPS3 + LPS decreased bacterial recovery the lung and blood at 24 and 48 h and increased survival. Microarray analysis of whole lung RNA revealed significant changes in the acute phase protein serum amyloid A (SAA) between noninfected and infected mice, which were attenuated by immunization. SAA transcripts were higher in the liver and lungs of infected controls, and SAA protein was elevated in serum, but decreased in PPS3-immunized mice. Thus, during a virulent pneumonia infection, prior immunization with PPS3 in an IgM-dependent manner as well as co-immunization with PPS3 + LPS attenuated pneumonia severity and promoted resolution of infection, concomitant with significant regulation of cytokine gene expression in the lungs, and acute phase proteins in the lungs, liver and serum. Each lung RNA sample represented an individual mouse, creating biological repeats for each treatment. In-vivo treatments were as follows: non-infected lung (vehicle-immunized) control (n=5), infected lung (vehicle-immunized) control at 48 hr post-inoculation (n=5), PPS3 and LPS co-immunized lung at 48 hr post-inoculation (n=4) and PPS3 and LPS co-immunized lung at 7 days post-inoculation (n=4).

Species:
mouse

Samples:
18

Source:
E-GEOD-45644

PubMed:
23389932

Updated:
Dec.12, 2014

Registered:
Nov.12, 2014


Factors: (via ArrayExpress)
Sample
GSM1111225 1
GSM1111226 1
GSM1111227 1
GSM1111228 1
GSM1111229 1
GSM1111230 1
GSM1111231 1
GSM1111232 1
GSM1111233 1
GSM1111234 1
GSM1111235 1
GSM1111236 1
GSM1111237 1
GSM1111238 1
GSM1111239 1
GSM1111240 1
GSM1111241 1
GSM1111242 1

Tags

  • cytokine
  • disease
  • lipopolysaccharide
  • liver
  • lung
  • pneumonia
  • polysaccharide
  • protein
  • serum

Other Formats

JSON    XML
  • About
  • Blog
  • Help
  • FAQ
  • Downloads
  • API
  • iPhone App
  • Email updates
© 2025 The Scripps Research Institute. All rights reserved. (ver 94eefe6 )
  • Terms of Use